home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

MICHAEL DuBOIS
Senior Vice President, Global Licensing & Strategic Alliances,
Schering-Plough Corporation
Kenilworth, New Jersey

Michael J. DuBois is senior vice president, Global Licensing and Strategic Alliances, for Schering-Plough Corporation.

DuBois joined Schering-Plough in his present position in September 2003. He is responsible for the acquisition of new products discovered outside Schering-Plough's laboratories to complement the activities of the company's internal drug discovery programs.

Previously, DuBois was senior vice president, Global Licensing, for Pharmacia Corporation, which has since merged with Pfizer. He also previously served as senior vice president, Corporate Licensing, for the former Pharmacia & Upjohn Company. During his tenure with Pharmacia, DuBois was instrumental in establishing companywide processes to improve Pharmacia's competitive position in pharmaceutical licensing.

DuBois holds B.S. degrees in chemistry and pharmacy from Rutgers, The State University of New Jersey. He earned an M.B.A. degree from the Rutgers Graduate School of Management.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.



Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough